Zobrazeno 1 - 8
of 8
pro vyhledávání: '"David Lohrberg"'
Autor:
David Lohrberg, Bernd Hartmann, Joachim Dissemond, Matthias Augustin, Lisa Goepel, Marco Humrich, Marco Blessmann, Guido Bruning, Holger Diener, M. Gutknecht
Publikováno v:
Int Wound J
Split-thickness skin grafting is a common procedure to treat different kinds of wounds. This systematic, multicentre, observational, cross-sectional study of adult patients with split-thickness skin graft (STSG) donor site wounds was conducted to eva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c559a96a36302504591e67a731ebb399
https://www.ncbi.nlm.nih.gov/pubmed/29243343
https://www.ncbi.nlm.nih.gov/pubmed/29243343
Autor:
David Lohrberg
Publikováno v:
Der Deutsche Dermatologe. 63:498-501
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::deb2d6ac37cc7703f0016eb8f48b1e0f
https://doi.org/10.1007/s15011-015-0284-2
https://doi.org/10.1007/s15011-015-0284-2
Autor:
Roman Faubel, David Lohrberg, Katharina Herberger, Eike Sebastian Debus, Matthias Augustin, Christine Blome, Lisa Goepel, Guido Bruning
Publikováno v:
Wound Medicine. 8:31-35
Background Patients with venous diseases may show marked reductions in health-related quality of life. The Freiburg Life Quality Assessment for venous diseases has been shown to be a valid and physical instrument. Objective The objective of this stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b489e74bfa57ae96f3e5fefad1836fd6
https://doi.org/10.1016/j.wndm.2015.01.002
https://doi.org/10.1016/j.wndm.2015.01.002
Publikováno v:
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 58:283-290
Hintergrund In der fruhen Nutzenbewertung nach dem Arzneimittelmarkt-Neuordnungsgesetz (AMNOG) ist die gesundheitsbezogene Lebensqualitat als ein Kriterium zur Quantifizierung des Zusatznutzens eines Arzneimittels verankert. Trotz dieser Vorgabe ist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3757e8fcc01642e688df2a4d8fcc90b7
https://doi.org/10.1007/s00103-014-2107-0
https://doi.org/10.1007/s00103-014-2107-0
Publikováno v:
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 17(7)
This study was financially supported by Janssen-Cilag GmbH, Neuss, Germany. We thank Luise Geithner, Joris Lehmann, and Nicole Wehber for their help with data collection. EARLY DRUG BENEFIT ASSESSMENT (EBA) Since January 2011, pharmaceutical manufact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b73372ae8cf2187283afa12ee55b9ef3
https://pubmed.ncbi.nlm.nih.gov/27201201
https://pubmed.ncbi.nlm.nih.gov/27201201
Publikováno v:
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 25(2)
In 2011, Germany introduced a new form of drug benefit assessment, linking reimbursement prices to drug benefit and making quality of life (QoL) one of the main benefit criteria. Thus, QoL outcomes co-determine drug prices in Germany. QoL has, howeve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44d99aed5a2b2b4d58974b51be42077a
https://pubmed.ncbi.nlm.nih.gov/26242250
https://pubmed.ncbi.nlm.nih.gov/26242250
Publikováno v:
The European journal of health economics : HEPAC : health economics in prevention and care. 18(2)
Since 2011, an early benefit assessment (EBA) of new drugs constricts free price setting in Germany. According to the Pharmaceutical Market Restructuring Act (AMNOG), pharmaceutical companies are obliged to demonstrate added benefit of new drugs over
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2caf1a5e55c5339d1ab1925e9491926b
https://pubmed.ncbi.nlm.nih.gov/26837412
https://pubmed.ncbi.nlm.nih.gov/26837412
Publikováno v:
Value in Health. 17:A437
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92b5b7585692acb83a9fc5f40a179cc8
https://doi.org/10.1016/j.jval.2014.08.1133
https://doi.org/10.1016/j.jval.2014.08.1133